Abstract
Short, intensive cycles of chemotherapy have resulted in improved survival in BurkittOs lymphoma/leukemia (BL) in adults. The prognosis of patients with immunodeficiency virus (HIV)-associated BL is considered to be poor, but these patients have seldom been treated with BL-specific protocols. However, a study (PETHEMA-LAL3/97) in which patients with BL were treated regardless of their HIV status failed to find differences between HIV-infected and immunocompetent individuals. Furthermore, patients who received highly active antiretroviral therapy (HAART) seemed to have a slightly better disease-free survival than those who did not (p=0.051). We extended the follow-up analysis to elucidate the role of HAART in the survival of HIV-infected patients included in the PETHEMA-LAL3/97 protocol.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acquired Immunodeficiency Syndrome / complications
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Antiretroviral Therapy, Highly Active*
-
Cyclophosphamide / therapeutic use
-
Cytarabine / therapeutic use
-
Dexamethasone / therapeutic use
-
Disease-Free Survival
-
Etoposide / therapeutic use
-
Female
-
Follow-Up Studies
-
Humans
-
Ifosfamide / therapeutic use
-
Leucovorin / therapeutic use
-
Leukemia / drug therapy*
-
Leukemia / etiology
-
Lymphoma, AIDS-Related / drug therapy*
-
Male
-
Methotrexate / therapeutic use
-
Middle Aged
-
Prednisone / therapeutic use
-
Treatment Outcome
-
Vincristine / therapeutic use
Substances
-
Cytarabine
-
Vincristine
-
Etoposide
-
Dexamethasone
-
Cyclophosphamide
-
Leucovorin
-
Ifosfamide
-
Prednisone
-
Methotrexate
Supplementary concepts
-
PETHEMA ALL-3-97 protocol